Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PEPG
stocks logo

PEPG

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.370
-45.59%
--
--
-0.347
-62.23%
--
--
-0.352
-49.64%
Estimates Revision
Stock Price
Go Up
up Image
+279.29%
In Past 3 Month
Wall Street analysts forecast PEPG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEPG is 10.00 USD with a low forecast of 3.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast PEPG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEPG is 10.00 USD with a low forecast of 3.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
1 Sell
Moderate Buy
Current: 5.310
sliders
Low
3.00
Averages
10.00
High
20.00
Current: 5.310
sliders
Low
3.00
Averages
10.00
High
20.00
H.C. Wainwright
Andrew Fein
Buy
maintain
$18 -> $20
2025-11-13
Reason
H.C. Wainwright
Andrew Fein
Price Target
$18 -> $20
2025-11-13
maintain
Buy
Reason
H.C. Wainwright analyst Andrew Fein raised the firm's price target on PepGen to $20 from $18 and keeps a Buy rating on the shares. A new U.S. composition of matter patent for PGN-EDODM1 securing exclusivity into the 2040s reinforces the durability of its myotonic dystrophy type 1 franchise, the analyst tells investors.
H.C. Wainwright
Andrew Fein
Buy
maintain
$12 -> $18
2025-10-28
Reason
H.C. Wainwright
Andrew Fein
Price Target
$12 -> $18
2025-10-28
maintain
Buy
Reason
H.C. Wainwright analyst Andrew Fein raised the firm's price target on PepGen (PEPG) to $18 from $12 and keeps a Buy rating on the shares. The firm believes Novartis' (NVS) acquisition of Avidity (RNA) "has reshaped sentiment across the neuromuscular oligonucleotide space." PepGen's recent rally still leaves the stock at a "steep discount" to peers despite delivering "best-in-class" myotonic dystrophy type 1 data, the analyst tells investors in a research note.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$8 -> $12
2025-09-25
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$8 -> $12
2025-09-25
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on PepGen to $12 from $8 and keeps a Buy rating on the shares. The company reported 53.7% mean splicing correction at 15 mg/kg in the FREEDOM single dose study, the highest level disclosed in myotonic dystrophy type 1 patients to date, the analyst tells investors in a research note. The firm says one patient experienced a transient, reversible renal biomarker elevation that although resolved without intervention, indicates that the program "might not be out of the woods yet." However, PepGen's nearly 54% correction sets a new benchmark and "strongly suggests that repeat dosing could yield clinically meaningful functional benefit," contends H.C. Wainwright.
Guggenheim
Debjit Chattopadhyay
initiated
$6
2025-09-09
Reason
Guggenheim
Debjit Chattopadhyay
Price Target
$6
2025-09-09
initiated
Reason
Guggenheim analyst Debjit Chattopadhyay initiated coverage of PepGen with a Buy rating and $6 price target.
Guggenheim
initiated
$6
2025-09-09
Reason
Guggenheim
Price Target
$6
2025-09-09
initiated
Reason
As previously reported, Guggenheim initiated coverage of PepGen with a Buy rating and $6 price target. The firm believes the stock "could trade higher by 5x to 10x over the next three quarters" following clarity from the ongoing Single Ascending Dose/Multiple Ascending Dose studies in Myotonic Dystrophy Type 1, but if the SAD/MAD data underwhelm it would expect management will return residual cash to shareholders. Key upcoming clinical readouts include 15 mg/kg SAD data to be presented on October 11 and 5 mg/kg MAD data during Q1, notes the analyst, who is "optimistic" about the company's ability to demonstrate clinically meaningful improvement in splicing and other biomarkers.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$14 -> $8
2025-05-29
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$14 -> $8
2025-05-29
downgrade
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for PepGen Inc (PEPG.O) is -3.81, compared to its 5-year average forward P/E of -2.67. For a more detailed relative valuation and DCF analysis to assess PepGen Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.67
Current PE
-3.81
Overvalued PE
-1.14
Undervalued PE
-4.19

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.35
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.20
Undervalued EV/EBITDA
-2.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 294713.82% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 294713.82% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PEPG News & Events

Events Timeline

(ET)
2025-11-12
07:31:58
PepGen reveals grant of patent for PGN-EDODM1
select
2025-11-12
07:20:09
PepGen announces Q3 earnings per share of 52 cents, below consensus estimate of 56 cents.
select
2025-10-28 (ET)
2025-10-28
08:45:01
Significant Borrowing Rate Hikes Among Liquid Assets
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-26NASDAQ.COM
Sarepta's Shares Climb Following Encouraging News on DM1 Treatment

  • Sarepta Therapeutics' Stock Surge: Shares of Sarepta Therapeutics rose 7% following positive updates on its phase I/II study of SRP-1003, a potential treatment for type 1 myotonic dystrophy, including successful patient enrollment and safety committee approval.

  • Milestone Payments and Partnerships: The announcement triggered a $200 million milestone payment to Arrowhead Pharmaceuticals, part of a multi-billion-dollar licensing deal, with Sarepta having previously made a $100 million payment earlier this year.

  • Investor Sentiment: Despite the stock's significant decline of nearly 85% year-to-date, investor optimism has increased due to the positive study updates, contrasting with challenges faced by other companies in the same therapeutic area.

  • Future Developments: Sarepta is currently dosing patients in the fourth cohort of the study and plans to begin the fifth cohort in early 2026, with initial data expected early next year for SRP-1003 and other clinical-stage programs.

[object Object]
Preview
4.0
11-17NASDAQ.COM
PepGen (PEPG) Price Target Raised by 17.65% to $10.20

  • Price Target Update: The average one-year price target for PepGen has been revised to $10.20 per share, reflecting a 17.65% increase from the previous estimate of $8.67, with a range from $3.03 to $21.00 per share.

  • Fund Sentiment: There are 159 funds reporting positions in PepGen, with a 7.43% increase in ownership over the last quarter, and total shares owned by institutions rising by 124.38% to 54,560K shares.

  • Major Shareholders: Ra Capital Management and Viking Global Investors significantly increased their holdings in PepGen, with Ra Capital raising its ownership by 46.72% and Viking by 57.43% over the last quarter.

  • Market Outlook: The put/call ratio for PepGen is 0.40, indicating a bullish sentiment among investors, while Fintel provides comprehensive investment research and data for individual investors and small hedge funds.

[object Object]
Preview
8.5
10-27SeekingAlpha
Dyne and PepGen Surge as Likely Winners from Novartis/Avidity Agreement

  • Market Reaction: Dyne Therapeutics and PepGen saw significant stock increases of approximately 41% and 21%, respectively, following Novartis' $12 billion acquisition of Avidity Biosciences.

  • Avidity's Developments: Avidity is advancing treatments for rare muscular dystrophies, including Del-zota for Duchenne muscular dystrophy and other candidates for myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy.

  • Dyne's Pipeline: Dyne Therapeutics is working on two candidates for myotonic dystrophy type 1, utilizing its proprietary FORCE platform, with data expected by mid-2026.

  • PepGen's Trials: PepGen is developing PGN-EDODM1 for myotonic dystrophy type 1 and is currently recruiting for two clinical trials, one in phase 1 and another in phase 2.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is PepGen Inc (PEPG) stock price today?

The current price of PEPG is 5.31 USD — it has increased 1.14 % in the last trading day.

arrow icon

What is PepGen Inc (PEPG)'s business?

PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.

arrow icon

What is the price predicton of PEPG Stock?

Wall Street analysts forecast PEPG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEPG is 10.00 USD with a low forecast of 3.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is PepGen Inc (PEPG)'s revenue for the last quarter?

PepGen Inc revenue for the last quarter amounts to -18.65M USD, decreased -19.49 % YoY.

arrow icon

What is PepGen Inc (PEPG)'s earnings per share (EPS) for the last quarter?

PepGen Inc. EPS for the last quarter amounts to -19356000.00 USD, decreased -20.01 % YoY.

arrow icon

What changes have occurred in the market's expectations for PepGen Inc (PEPG)'s fundamentals?

The market is revising No Change the revenue expectations for PEPG for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 279.29%.
arrow icon

How many employees does PepGen Inc (PEPG). have?

PepGen Inc (PEPG) has 81 emplpoyees as of December 05 2025.

arrow icon

What is PepGen Inc (PEPG) market cap?

Today PEPG has the market capitalization of 365.05M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free